Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Catalyst begins phase II trial of CPP-109 for cocaine dependence

July 13, 2007

Recent Auspex patent discloses new treatment option for substance abuse and dependence

July 6, 2007

Positive phase I/II results for ALKS-29 in alcohol-dependent patients

July 4, 2007

New agents for substance abuse imparted in recent Auspex patent

June 25, 2007

NICE recommends use of Champix on U.K.'s National Health Service

June 1, 2007

Mucosal trivalent vaccine against botulism toxin identified at DOR BioPharma

May 31, 2007

NT69L and LY-379268 studied for possible use in nicotine addiction

May 29, 2007

Exjade labeling receives new Warning and Adverse Reactions information

May 28, 2007

Nalmefene licensing agreement enters into force

May 25, 2007

AEOL-10150 to be studied in mustard gas-mediated lung injury

May 25, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...